You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Developing EV surface proteins as biosignatures for Alzheimer's disease (AD)

    SBC: Tymora Analytical Operations, LLC            Topic: NIA

    PROJECT SUMMARY The rising number of Americans currently living with Alzheimer’s disease (AD) demands pressing therapeutic and diagnostic solutions. The consensus is that early detection is critical to delay and better manage the disease. The recent discovery of extracellular vesicles (EVs) and their potentially important cellular functions in neuronal-glial communication, synaptic plasticity, o ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. A Vaccine for Acute Flaccid Myelitis

    SBC: Aleph Therapeutics, Inc.            Topic: NIAID

    SUMMARYIn 2014 the United States experienced an outbreak of a previously unknown neurological disease with polio-like symptoms later known as acute flaccid myelitis (AFM). A biennial surge in cases of AFM in 2016 and 2018 has alarmed public health officials. Since then, rapidly accumulating clinical, immunological, and epidemiological evidence has pointed to EV-D68 as the major causative agent of ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. High Density Cell Respirator (HDCR) for the production of vectors, viruses and vaccines

    SBC: XDemics Corporation            Topic: NCATS

    PROJECT SUMMARY/ABSTRACT This Phase I/II STTR Fast Track proposal responds to the call from the 2018/2019 NCATS SBIR/STTR Research Priorities to develop technologies so that “new treatments and cures for disease can be delivered to patients more quickly”. The production of life-altering gene editing vectors, cancer killing viruses, and life- saving vaccines currently depends on traditional cel ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Novel OCT Technology for Detection of Occult Sperm in the Testes inNon- Obstructed Azoospermia.

    SBC: Unasper, Inc.            Topic: NICHD

    Non-obstructive azoospermia (NOA), a lack of sperm in the ejaculate due to defective spermatogenesis, affects as many as 100,000 men in the US, and represents an unmet medical need because many of these men would like to father children, but cannot without surgical intervention. Current therapy for such men is suboptimal, because it relies upon microsurgical testicular sperm extraction (micro-TESE ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. A Novel, Field-Deployable, Biomimetic Narcotics Detector for the Identification of Fentanyl and Other Synthetic Opioids

    SBC: SEACOAST SCIENCE, INC.            Topic: NIDA

    AbstractThe alarming scope of the rapidly growing opioid epidemic has commanded the nation’s attention. The White House’s Council of Economic Advisers estimates that in 2015, the economic cost of the opioid crisis was over $504.0 billion (2.8% of GDP); and it is only expected to continue rising. Today, 1 in 5 fatalities amongst young adults is opioid related; with half a million fatal overdose ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. A method for accurate and sensitive detection of HIV drug-resistant minority variants

    SBC: Medosome Biotec, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Drug resistance to HIV is a major threat to achieving long term viral suppression in HIV individuals Up to of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes and incomplete viral suppression and virologic failure are often associated with drug resistance Therefore current DHHS guideline recomme ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Preventing liver fibrosis in alcoholic hepatitis by enhancing liver regenerative capacity via transient telomere extension using lipid nanoparticle-encapsulated TERT mRNA

    SBC: REJUVENATION TECHNOLOGIES INC            Topic: 400

    Abstract Rejuvenation Technologies Inc. (RTI) aims to prevent liver fibrosis in alcoholic hepatitis (AH) by enhancing liver regenerative capacity. AH is an acute form of alcoholic liver disease with mortality of up to 50% within 1 month of presentation. Most AH patients exhibit advanced fibrosis/cirrhosis, which contributes to acute-on-chronic liver failure. RTI will ameliorate/prevent this fibros ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. High speed Intraoperative Assessment of Breast Tumor Margin using MarginPAT

    SBC: Vibronix, Inc.            Topic: O

    After a breast conserving therapy histology is often performed to check whether the excised tumor specimen is surrounded by a sufficient amount of normal tissue If a positive margin is identified then a second operation will be performed Currently the re operation rate is which raises a need for intraoperative detection of residual cancers The current intraoperative tools for margin ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Mechanistic Studies of a Novel Small Molecule HIV Inhibitor

    SBC: ADVANCED GENETIC SYSTEMS, INC.            Topic: 100

    DESCRIPTION provided by applicant There is a significant need for novel HIV therapies given the emergence of viruses resistant to existing drug regimens The Rev RRE protein RNA interaction in HIV plays an essential role in the transport of viral mRNA from the nucleus to the cytoplasm where it can be translated or packaged Previously we identified the thienopyridine scaffold that inhibited HIV ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. A Novel STAT3 Inhibitor Targeting its DNA-Binding Site for Drug Development

    SBC: QRKANSWER LLC            Topic: NCI

    DESCRIPTION provided by applicant Cancer is a major public health problem and a leading cause of mortality claiming more than half million lives every year in the US While major progresses have been made in developing targeted anticancer therapeutics many cancers such as lung cancers have no effective treatments Unfortunately many ideal oncogenic targets including transcription factors for ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government